Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline plc : GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash

share with twitter share with LinkedIn share with facebook
share via e-mail
09/13/2012 | 02:29pm CEST

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Issued: Thursday 13 September 2012, London, UK

GlaxoSmithKline plc (LSE: GSK) today announces that it has acquired five million newly issued shares of Response Genetics Inc. (RGI) (NASDAQ: RGDX) common stock at a purchase price of US$1.10 per share in cash. As a result, GSK now owns approximately 15.2% of the expanded share capital of RGI.

This transaction builds on the relationship GSK and RGI have been building over the years in the diagnostics field of oncology and vaccines. RGI performs companion diagnostic tests and other related activities for GSK's immunotherapies and oncology pipeline candidates.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502


Stephen Rea

+44 (0) 20 8047 5502


Sarah Spencer

+44 (0) 20 8047 5502


David Daley

+44 (0) 20 8047 5502


US Media enquiries:

Kevin Colgan

+1 919 483 2933

(North Carolina)

Melinda Stubbee

+1 919 483 2510

(North Carolina)

Sarah Alspach

+1 202 715 1048

(Washington, DC)

Jennifer Armstrong

+1 215 751 5664


Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543


Tom Curry

+ 1 215 751 5419


Gary Davies

+ 44 (0) 20 8047 5503


James Dodwell

+ 44 (0) 20 8047 2406


Jeff McLaughlin

+ 1 215 751 7002


Ziba Shamsi

+ 44 (0) 20 8047 3289


GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
06:04a PFIZER : U.S. pharmaceutical firms to extend investments in Egypt
08/18 GLAXOSMITHKLINE : taps Baltimores Insilico for AI-based drug discovery
08/17 RESEARCH FROM GLAXOSMITHKLINE PLC YI : lamotrigine and fatal...
08/17 NEW CYTOKINES FINDINGS FROM GLAXOSMI : A Reversible and Selective Antagonist of ..
08/17 GLAXOSMITHKLINE : New Data from GlaxoSmithKline plc Illuminate Findings in Vacci..
08/17 Drugmaker Hikma trims sales forecasts, shares fall
08/15 GLAXOSMITHKLINE PLC. (ADR)(NYSE : GSK) Restructuring Takes A Toll on Ionis Pharm..
08/14 Featured Company News – GlaxoSmithKline Drops Options to Licence Inoter..
08/11 GLAXOSMITHKLINE PLC (ADR) (NYSE : GSK) And Rolls Royce To Expect UK Fraud Office..
More news
News from SeekingAlpha
08/18 SNIPPET ROUNDUP : Transparency For Straumann But A Black Box For Pfizer
08/17 'Safer' Dividend Follower Favorites And Rogues Led By RAIT Financial & Chico,..
08/16 Biogen's Alzheimer's Hope Tops The Sector's Most Valuable Pipeline Projects
08/15 BRISTOL-MYERS SQUIBB : HIV Franchise Was Never A Big Part Of The Game Plan
08/14 Gilead's Newer Tenofovir Patents Might Aid Its HIV Franchise
Financials ( GBP)
Sales 2017 30 168 M
EBIT 2017 8 507 M
Net income 2017 4 165 M
Debt 2017 14 104 M
Yield 2017 5,37%
P/E ratio 2017 19,44
P/E ratio 2018 15,79
EV / Sales 2017 2,90x
EV / Sales 2018 2,80x
Capitalization 73 240 M
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 17,5  GBP
Spread / Average Target 17%
EPS Revisions
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Roy Malcolm Anderson Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.12%355 979
NOVARTIS8.84%216 915
ROCHE HOLDING LTD.4.99%216 699
PFIZER0.59%194 554